Oncovita

Oncovita is an Institut Pasteur spin-off developing immuno-virotherapies for solid cancers, based on a genetically modified measles vaccine virus. Its lead candidate, MVdeltaC, is an oncolytic virus capable of inducing immunogenic cell death, and has shown promising preclinical results in numerous models, including immunocompetent mice. This virus specifically targets tumour cells overexpressing the CD46 receptor and induces a durable anti-tumour immune response.